Craniofaringioma cístico: quimioterapia intratumoral com interferon alfa

OBJECTIVE: To assess whether the cystic craniopharyngiomas can be controlled with the use of intratumoral applications of interferon alpha. METHOD: Nineteen patients with the diagnosis of cystic craniopharyngioma were treated with intratumoral chemotherapy with interferon alpha from January 2002 to April 2006. All patients underwent placement of an intracystic catheter connected to an Ommaya reservoir. Through this reservoir were made applications during chemotherapy cycles. Each cycle corresponded to application of 3,000,000 units of interferon alpha three times per week on alternate days totalizing 36,000,000 units. Response to treatment was evaluated by calculating the tumor volume on MRI control after one, three and six months after the end of each cycle. Patients who developed worsening of symptoms or who had insignificant reduction in tumor volume during follow-up underwent repeat cycle chemotherapy. RESULTS: Four patients received four cycles of chemotherapy, three patients received three cycles, six patients received two cycles and six patients received one. The lower percentage of reduction in tumor volume was 60% and the bigger reduction was 98.37%. Eleven patients had a reduction greater than 90%. Five patients had a tumor reduction between 75 and 90% and in three patients the tumors were reduced by less than 75%. No deaths occurred during treatment and side effects of interferon alpha were well tolerated. No treatment was discontinued. Follow-up after the last application ranged from one year and five months to three years and nine months. CONCLUSION: The intratumoral chemotherapy with interferon alpha decreases the volume of cystic craniopharyngiomas and so far can be considered a new therapeutic alternative.OBJETIVO: Avaliar se os craniofaringiomas císticos podem ser controlados com aplicações intratumorais de interferon alfa. MÉTODO: De janeiro de 2002 a abril de 2006, 19 pacientes foram submetidos à colocação de um cateter intracístico conectado a reservatório de Ommaya para aplicações intratumorais de ciclos de 36.000.000 de unidades de interferon alfa. A resposta ao tratamento foi avaliada pelo cálculo do volume tumoral na ressonância magnética de controle ao término de cada ciclo. RESULTADOS: Os pacientes receberam de um a quatro ciclos de quimioterapia. Onze pacientes apresentaram uma redução do volume tumoral maior que 90%; cinco pacientes apresentaram uma redução entre 75% e 90% e três pacientes uma redução menor de 75%. Não houve óbitos durante o tratamento e os efeitos colaterais do inferferon alfa foram bem tolerados. Nenhum tratamento foi interrompido. CONCLUSÃO: A quimioterapia intratumoral com interferon alfa diminui o volume dos craniofaringeomas císticos e pode ser considerada uma nova alternativa terapêutica.Federal University of São Paulo Department of Neurosurgery and Section of Pediatric NeurosurgeryFederal University of São Paulo Department of PediatricsFederal University of São Paulo Laboratory of Pediatric Oncology InstituteUNIFESP, Department of Neurosurgery and Section of Pediatric NeurosurgeryUNIFESP, Department of PediatricsUNIFESP, Laboratory of Pediatric Oncology InstituteSciEL

Valproic acid and Hedgehog pathway: A possible drug resistance mechanism in medulloblastoma?

Universidade Federal de São Paulo, Dept Pediat, Pediat Oncol Inst GRAACC, São Paulo, BrazilUniversidade Federal de São Paulo, Div Genet, Dept Morphol & Genet, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Pathol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Neurol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Pediat, Pediat Oncol Inst GRAACC, São Paulo, BrazilUniversidade Federal de São Paulo, Div Genet, Dept Morphol & Genet, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Pathol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Neurol, São Paulo, BrazilWeb of Scienc

Modulation of AKT, CTNNB1, GLI1, KDM6A, KDM6B, NOTCH2, PTCH1 and Tert Genes Expression in Medulloblastoma Cell Lines Exposed to Drug Treatment

IOP GRAACC UNIFESP, Paediat Oncol Inst, Dept Paediat, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Morphol & Genet, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Neurol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pathol, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Clin & Expt Oncol, Sao Paulo, BrazilPaediatric Oncology Institute ‐ IOP/GRAACC/Universidade Federal de São Paulo (UNIFESP), Department of Paediatrics, Sao Paulo, BrazilUniversidade Federal de São Paulo (UNIFESP), Department of Morphology, Sao Paulo, BrazilUniversidade Federal de São Paulo (UNIFESP), Department of Neurology, Sao Paulo, BrazilUniversidade Federal de São Paulo (UNIFESP), Department of Pathology, Sao Paulo, BrazilFederal University of Sao Paulo, Department of Clinical and Experimental Oncology, Sao Paulo, BrazilWeb of Scienc